On July 5, 2021, Haichang Biotech announced the appointment of Dr. Men Yuxin (Angela Men) as the company's Chief Medical Officer, who will be fully responsible for the implementation of the company's medical strategies and global clinical development strategies. Dr. Men's joining will substantially facilitate the global clinical trial layout of the Haichang Biotech’s RNA drugs and phospholipid nanoparticle pipeline projects, help the company in establishing a more stable and reliable medical system, to better embrace the opportunities and challenges emerging in the future.
Dr. Men joined the US Food and Drug Administration (FDA) in 2003 and has served as senior and special approving officer for clinical pharmacology and head of drug approval team at the Center for Drug evalsuation and Research (CDER), where she was mainly responsible for the IND/NDA/BLA on antineoplastic drugs and neurodrugs. In her nearly 18 years of work and experience in drug supervision, she has personally been responsible for approving over 2,000 investigational new drug trial applications and new drug marketing applications. She has received more than 50 awards from FDA, including Outstanding Service Award, Distinguished Tutor Award, Outstanding Leadership Award and Outstanding Regulatory Science Award. Dr. Men has been the head of numerous research projects on drug approval, received 12 FDA research grants, led the development of several FDA guidelines, and served as an organizer or speaker of relevant academic conferences on many occasions. She is also a member of the Federal Asian Pacific American Council (FAPAC) and an assistant president of the Community Development Department, and she has vigorously participated in and promoted the activities for the Asian-Pacific Americans. After graduating from Tianjin Medical University with a bachelor's degree in clinical medicine, Dr. Men Yuxin worked as a neurologist in the Second Hospital of Tianjin Medical University and participated in Phase I clinical trials of drugs. After going to the United States, she obtained a doctorate in pharmaceutical sciences from the School of Pharmacy of Virginia State University, where she completed the Phase I clinical trial as the PI.
Dr. Men Yuxin:
“I am so honored to be a member of Haichang Biotech and White Oak Medicine. Haichang Biotech is a high-tech biomedical company with abundant international resources and professional talent team. It has formed well-designed layout in projects on innovative nucleic acid drugs and cutting-edge complex injection products and accomplished highly efficient advancements in these aspects, providing very promising prospects. Considering that a number of Haichang’s RNA pipeline projects are currently in the key stage of clinical trial, I sincerely intend to fulfill more achievements with my personal resources available at Haichang Biotech, and I really look forward to working together with Haichang’s top-level team to contribute to its global product development, and accelerate the commercial industrialization of Haichang’s biological product pipelines.”
Dr. Zhao Xiaobin, president of Haichang Biotech:
“We are so delighted to have Dr. Men as the chief medical officer of Haichang Biotech. As an extensively experienced clinician and drug regulatory expert, Dr. Men Yuxin has accomplished impressively remarkable results and achievements in such areas as the advancement, evalsuation and approval of antineoplastic drugs and neurodrugs. Dr. Men's extensive experience in clinical medicine and drug marketing applications is of critical significance for the development of Haichang Biotech. Over the rapid development in the nearly past ten years, Haichang Biotech has established its appropriately indispensable capabilities in setting up proper platforms for the whole-process drug development procedures from early discovery, process development, clinical development to commercial production. We have high-level expectations that Dr. Men will definitely achieve outstanding results together with our clincal medicine team in the successful initiation of more clinical trials of drugs and their marketing so as to meet the highly unmet medical needs in clinical treatment and prevention of various cancers and infectious diseases.”
About Haichang Biotech
Founded in 2013 by Zhao Xiaobin, a former senior evalsuation expert at FDA, Zhejiang Haichang Biotech Co., Ltd is a national high-tech enterprise specializing in the research and development of biomedical technologies. With the core values of “Sharing for All, Enterprising Drive, Pursuit of Truth, Maintaining A Pragmatic Attitude”, the company focuses on the development of pharmaceutical products including mRNA vaccines, RNA drug delivery and liposomal nanodrugs etc. Targeting the international market, the company has been executing the strategy of perfectly combining innovations and generics in the development of drugs for use in tumors, analgesia and anti-infection. The company has set up highly competitive product pipelines and aims to assert itself as an international pharmaceutical company integrating R&D, manufacturing and marketing.
